Compare · TNYA vs TPST
TNYA vs TPST
Side-by-side comparison of Tenaya Therapeutics Inc. (TNYA) and Tempest Therapeutics Inc. (TPST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while TPST focuses on Biotechnology: Pharmaceutical Preparations.
- TNYA is the larger of the two at $93.1M, about 8.9x TPST ($10.5M).
- TPST has been more active in the news (10 items in the past 4 weeks vs 1 for TNYA).
- Both have 7 recent analyst ratings on file.
- Company
- Tenaya Therapeutics Inc.
- Tempest Therapeutics Inc.
- Price
- -
- -
- Market cap
- $93.1M
- $10.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 10
- Recent ratings
- 7
- 7
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Tempest Therapeutics Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.
Latest TNYA
- SEC Form PRE 14A filed by Tenaya Therapeutics Inc.
- Chief Executive Officer Ali Faraz was granted 122,000 shares, increasing direct ownership by 29% to 539,782 units (SEC Form 4)
- Chief Medical Officer Tingley Whittemore was granted 49,000 shares, increasing direct ownership by 23% to 263,073 units (SEC Form 4)
- Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
- SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.
- Chief Executive Officer Ali Faraz sold $15,778 worth of shares (22,232 units at $0.71), decreasing direct ownership by 5% to 417,782 units (SEC Form 4) to cover taxes
- Chief Medical Officer Tingley Whittemore sold $5,270 worth of shares (7,424 units at $0.71), decreasing direct ownership by 3% to 214,073 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Tenaya Therapeutics Inc.
- SEC Form S-8 filed by Tenaya Therapeutics Inc.
- SEC Form 10-Q filed by Tenaya Therapeutics Inc.
Latest TPST
- SEC Form PRE 14A filed by Tempest Therapeutics Inc.
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
- SEC Form D filed by Tempest Therapeutics Inc.
- SEC Form 4 filed by Director Smith Nancy Freda
- SEC Form 3 filed by new insider Smith Nancy Freda
- SEC Form 424B3 filed by Tempest Therapeutics Inc.
- SEC Form EFFECT filed by Tempest Therapeutics Inc.
- Tempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- SEC Form S-3 filed by Tempest Therapeutics Inc.
- Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors